We propose a University of Maryland Center of Excellence in Regulatory Science and Innovation (UM- CERSI) through a consortia of two leading sister campuses within the University System of Maryland, and the FDA. This proposal leverages the engineering, device, and technologies strengths at UMCP with the biomedical and health outcomes strengths at UMB. These strengths at UMCP and UMB, in concert with FDA, will allow for innovations in regulatory science in three areas: Project 1. Improving pre-clinical assessments of safety and efficacy Project 2. Ensuring readiness to evaluate innovative and emerging technologies Project 3. Harnessing diverse data through information sciences to improve health outcomes """"""""Improving pre-clinical assessments of safety and efficacy"""""""" will focus on membrane transporters in drug development, hepatotoxicity biomarkers, and personalized medicine. """"""""Ensuring readiness to evaluate innovative and emerging technologies"""""""" will focus on performance of optical imaging and therapeutic systems, biocompatibility of stents and vascular grafts, and engineered cartilage constructs. """"""""Harnessing diverse data through information sciences to improve health outcomes"""""""" will focus on evaluation of risk evaluation and mitigation strategies, as well as infrastructure support and methods development to support decision science within pharmaceutical safety and effectiveness studies.
Three Specific Aims are: 1. Establish and Build Mechanisms for Scientific Exchange and Training;2. Create New Opportunities for Collaborative Regulatory Science Research;and 3. Establish Core Program Support and Management Plan to Ensure Success. Scientific exchange and training will entail formalized Center-wide programs including a CERSI Day, formalized programs in three proposed areas (e.g. quarterly lectures, workshops, semester courses, Visiting Scientist program, resource centers), casual discussions, as well as collaborative graduate student research. The sum of these activities will be a vibrant, cutting edge Center that stimulates innovative thought, disseminates understanding of regulatory sciences and practices, and generates new knowledge in support of the FDA's fundamental mission - to promote and protect the public health. These regulatory sciences advances will also promote the Critical Path Initiative toward more effective and efficient product development and evaluation.
We propose a University of Maryland Center of Excellence in Regulatory Science (UM-CERSI) that involves the University of Maryland in Baltimore (UMB), the University of Maryland College Park (UMCP), and the FDA, with scientific exchange, research, academic, and outreach components. The mission of the Center will be to foster the development of regulatory science - the science of developing new tools, standards and approaches to assess the safety, efficacy, quality and performance of FDA-regulated products.
|Zhu, Peng; Ye, Zhi; Guo, Dong et al. (2018) Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2). Pharm Res 35:243|
|Guo, Dong; Yang, Hong; Li, Qing et al. (2018) Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. Pharm Res 35:204|
|Burcu, Mehmet; Zito, Julie M; Safer, Daniel J et al. (2017) Association of Antidepressant Medications With Incident Type 2 Diabetes Among Medicaid-Insured Youths. JAMA Pediatr 171:1200-1207|
|Yang, Hong; Guo, Dong; Obianom, Obinna N et al. (2017) Multidrug and toxin extrusion proteins mediate cellular transport of cadmium. Toxicol Appl Pharmacol 314:55-62|
|Pennap, Dinci; Burcu, Mehmet; Safer, Daniel J et al. (2017) Hispanic Residential Isolation, ADHD Diagnosis and Stimulant Treatment among Medicaid-Insured Youth. Ethn Dis 27:85-94|
|Obianom, Obinna N; Coutinho, Ana L; Yang, Wei et al. (2017) Incorporation of a Biguanide Scaffold Enhances Drug Uptake by Organic Cation Transporters 1 and 2. Mol Pharm 14:2726-2739|
|Li, Qing; Yang, Hong; Guo, Dong et al. (2016) Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. Drug Metab Dispos 44:489-94|
|Burcu, Mehmet; Safer, Daniel J; Zito, Julie M (2016) Antipsychotic prescribing for behavioral disorders in US youth: physician specialty, insurance coverage, and complex regimens. Pharmacoepidemiol Drug Saf 25:26-34|
|Dong, Zhongqi; Li, Qing; Guo, Dong et al. (2015) Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver. J Pharm Sci 104:2864-76|
|Dong, Zhongqi; Ekins, Sean; Polli, James E (2015) A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide. Int J Pharm 478:88-95|
Showing the most recent 10 out of 21 publications